From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) convened in Paris, France, bringing together leading hematologists, researchers, and clinicians from around the world. Against the backdrop of rapid therapeutic innovation, multiple myeloma (MM) stands at a transformative moment in its history. Over the past two decades, treatment has evolved from conventional chemotherapy to targeted therapies, and now into an era defined by immunotherapy and precision medicine.At this year’s congress, Professor Kenneth Anderson, Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute and Harvard Medical School, delivered a landmark keynote presentation on the future of MM therapy. His lecture highlighted major advances ranging from frontline immunotherapy and microenvironment modulation to emerging definitions of clinical cure. Drawing upon international consensus efforts and cutting-edge clinical data, Professor Anderson outlined a future in which durable treatment-free survival—and potentially cure—may become an achievable goal for many patients.
Reshaping the Treatment Paradigm: Beyond Transplant Toward Fixed-Duration Therapy
For decades, autologous stem cell transplantation (ASCT) has represented a cornerstone of treatment for transplant-eligible MM patients. However, the emergence of highly effective induction regimens is beginning to challenge the traditional reliance on transplantation.
Professor Anderson compared findings from the PERSEUS and MIDAS studies to illustrate this paradigm shift. The PERSEUS trial demonstrated that quadruplet therapy with daratumumab plus VRd (D-VRd), followed by ASCT and maintenance therapy, may achieve progression-free survival (PFS) approaching 17 years in standard-risk patients.
At the same time, results from the MIDAS study suggest that patients receiving the highly active Isa-KRd regimen (isatuximab, carfilzomib, lenalidomide, and dexamethasone) achieved comparable rates of minimal residual disease (MRD) negativity and clinical benefit regardless of whether ASCT was subsequently performed. These findings raise the possibility that deep drug-induced responses may increasingly substitute for transplant-based consolidation in selected patients.
Equally noteworthy are emerging maintenance data indicating that two years of fixed-duration RVD or KRd maintenance may provide outcomes comparable to indefinite maintenance therapy. Such results suggest a future shift away from continuous treatment toward finite, highly effective therapeutic courses.
Beyond reducing treatment burden, fixed-duration strategies could significantly lessen cumulative toxicities and financial costs while bringing the field closer to the ultimate objective of cure rather than disease control.
Immunotherapy Moves to the Frontline: Early Intervention and Dual-Target Strategies
The integration of immunotherapy into earlier disease settings represents one of the most important developments in contemporary MM treatment.
Professor Anderson highlighted several studies demonstrating the remarkable efficacy of both CAR-T cell therapy and bispecific antibodies when introduced early in the disease course.
In the GMMG-HD10 study, the BCMA/CD3 bispecific antibody teclistamab combined with D-RVd induction achieved a remarkable 100% MRD negativity rate before transplantation, underscoring the power of early immune intervention in eliminating residual disease.
Meanwhile, the ongoing CARTITUDE-6 study is evaluating whether the BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel) can directly replace ASCT as frontline consolidation therapy. If successful, such an approach could fundamentally redefine treatment standards for transplant-eligible patients.
For transplant-ineligible individuals, particularly older or frail patients, combinations such as teclistamab plus daratumumab have also demonstrated impressive MRD negativity rates while maintaining acceptable tolerability profiles.
Professor Anderson also emphasized the biological synergy between proteasome inhibitors and immunotherapy. Proteasome inhibitors promote immunogenic tumor cell death while simultaneously increasing BCMA expression on plasma cells, thereby enhancing the efficacy of CAR-T cells and bispecific antibodies.
Furthermore, next-generation dual-target and multispecific constructs—including BCMA/CD19 and BCMA/GPRC5D-directed therapies—are being developed to address antigen escape, a key mechanism of relapse. Early findings from studies such as MajesTEC-3 have already demonstrated striking reductions in disease progression risk, with hazard ratios as low as 0.17.
Understanding the Microenvironment: The Foundation of Precision Cure
Achieving durable remission and cure requires more than eliminating malignant plasma cells; it also demands a comprehensive understanding of the tumor microenvironment that supports disease persistence.
Professor Anderson described how the progression from monoclonal gammopathy of undetermined significance (MGUS) to active MM is accompanied by a profound shift from immune surveillance to immune suppression within the bone marrow.
Through detailed immune profiling, investigators have identified a distinctive signature among long-term survivors characterized by robust immune reconstitution and enrichment of interferon-gamma–producing CD8-positive T cells.
Conversely, relapsed patients often exhibit profound CD8-positive T-cell exhaustion accompanied by increased expression of multiple immune checkpoint molecules.
While BCMA- and GPRC5D-directed therapies have delivered unprecedented clinical outcomes, resistance remains an ongoing challenge. Loss or downregulation of target antigens can eventually compromise therapeutic efficacy.
Professor Anderson therefore emphasized the importance of precision patient stratification. Identifying individuals with favorable baseline immune characteristics—particularly those with functional cytotoxic T-cell populations—may allow clinicians to better predict response to immunotherapy and personalize treatment intensity accordingly.
Preventing Progression: Early Intervention in High-Risk Smoldering Myeloma
One of the most exciting opportunities for achieving cure may lie in treating disease before it becomes fully symptomatic.
For patients with high-risk smoldering multiple myeloma (SMM), Professor Anderson advocated a strategy of proactive intervention rather than observation alone.
Historically, SMM management relied on watchful waiting. However, emerging evidence suggests that early treatment can dramatically alter disease trajectory.
Fixed-duration treatment with ixazomib, lenalidomide, and dexamethasone has produced exceptional outcomes, with MRD-negative patients achieving five-year PFS rates approaching 100%.
Even more striking are results published in Nature Medicine demonstrating that cilta-cel induced 10⁻⁶ MRD negativity in all treated SMM patients. Similarly, teclistamab has generated deep responses in this setting.
These findings suggest that high-risk SMM may no longer represent a disease state to monitor passively but rather an opportunity for preventive cure through eradication of microscopic disease before symptomatic progression occurs.
Emerging Technologies: In Vivo CAR-T and Immune Enhancement
Looking beyond current treatment paradigms, Professor Anderson presented several highly innovative therapeutic approaches that could further transform the field.
Among them is the development of in vivo CAR-T technologies, including investigational platforms such as KLN-1010. Rather than requiring ex vivo T-cell engineering and reinfusion, these approaches aim to generate CAR-T cells directly within the patient using viral vectors or nanoparticle delivery systems.
Such technologies could dramatically simplify treatment logistics and expand global access to cellular therapy.
Another promising strategy involves BCMA mRNA vaccines administered following CAR-T or bispecific antibody treatment to reinforce immune surveillance and prolong remission duration.
Novel immune targets are also emerging. Recent studies have identified β2-microglobulin (β2M) signaling through the inhibitory receptor LILRB1 as a contributor to immune suppression. Blocking this pathway appears capable of restoring both T-cell and natural killer (NK) cell function, offering a potential new avenue for overcoming resistance and enhancing anti-myeloma immunity.
Redefining Clinical Cure in Multiple Myeloma
Perhaps the most historic component of Professor Anderson’s presentation was the introduction of a standardized framework for defining clinical cure in multiple myeloma, developed through international consensus discussions at the IMS summit.
According to this proposed framework, clinical cure requires three key criteria:
1. Five Years Free From Disease
Patients must remain free of disease progression for at least five years after discontinuation of all anti-myeloma therapy.
2. Sustained Deep Remission
MRD negativity must be maintained throughout this period using highly sensitive next-generation flow cytometry or next-generation sequencing assays capable of detecting disease at the 10⁻⁶ level.
3. Imaging Negativity
Functional imaging studies, including PET-CT, must demonstrate no evidence of active disease both at treatment completion and at the five-year assessment point.
By transforming the previously abstract concept of cure into a measurable and clinically actionable endpoint, this framework represents a landmark milestone for the field.
Conclusion
Professor Kenneth Anderson’s vision for the future of multiple myeloma reflects a field undergoing a profound transformation—from chemotherapy to immunotherapy, from disease control to disease eradication, and from lifelong treatment to the possibility of treatment-free survival.
Advances in frontline immunotherapy, MRD-guided decision-making, immune microenvironment profiling, cellular therapy, and preventive intervention are converging toward a common goal: achieving durable, treatment-free remission for an increasing proportion of patients.
While significant challenges remain, COMy 2026 delivered a powerful message. Multiple myeloma is no longer viewed solely as a chronic incurable malignancy. Instead, through increasingly precise biological understanding and highly effective immune-based therapies, the prospect of clinical cure has moved from aspiration to a realistic and measurable objective.
The road ahead is still being built, but for the first time in the history of multiple myeloma, it is becoming possible to envision a future in which patients are not merely living longer with their disease—they are living beyond it.
